Resource Center

More to Explore - Information About Blood Cancers for Patients, Families and Healthcare Professionals

The Word:


January 21, 2014 - Myeloma- Update on Research and Treatment from the American Society of Hematology (ASH®) Annual Meeting

Your order contains  item(s)  View Order

Note: The free Adobe Acrobat Reader® is required to view and print Adobe PDF files, and the free Windows Media Player or RealPlayer is required to listen to the MP3 audio files.

Date: January 21, 2014
Time: 1:00 p.m. - 2:30 p.m. ET
Location: Telephone/Web
View: Program Slides
Read: Newsletter | Transcript
Listen: Presentation | Q&A Session
Access: Virtual Lecture 

Topics Covered

  • Current and emerging myeloma treatment options
  • Updates on myeloma maintenance therapy
  • The role of clinical trials in the advancement of treatment
  • Advances in treatment side effects management
  • Communicating with your healthcare team


Robert Z. Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor, Director, Myeloma Section
Departments of Lymphoma/Myeloma and Experimental Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX

Questions Asked by the Myeloma Community

  • Please explain why myeloma is a blood cancer, not a bone cancer?
  • Can you explain the P value (a measure of significance) seen in many of the slides?
  • Is there any information on secondary cancers associated with lenalidomide (Revlimid®)?
  • Will monoclonal antibodies be effective for smoldering myeloma?
  • Is autologous stem cell transplantation still the standard of care?
  • Can you address the use of curcumin, resveratrol and quercetin supplements in patients with smoldering multiple myeloma?
  • What is your best guess about when an oral proteasome inhibitor (such as ixazomib) will be approved for Myeloma?
  • Will the studies involving engineered T-cells, like the studies being held at the University of Pennsylvania be helpful for myeloma patients?
  • Has there been progress in developing standard measurements for minimal residual disease (MRD)?
  • What are the pluses and minuses of bortezomib (Velcade®) delivery, via subcutaneous injection versus IV administration?
  • Is the major shortage of the drug Doxorubicin (Doxil®) affecting myeloma treatment?
  • What does it mean if your lactate dehydrogenase (LDH) increases?
  • Do you regularly use PET or CT scans for regular disease evaluation?
  • How long can one safely take lenalidomide (Revlimid®)?

Sponsors and Supporters

This program is sponsored by The Leukemia & Lymphoma Society and supported by grants from Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals and Bristol-Myers Squibb.

This meeting is not sponsored, sanctioned by, or part of the 55th Annual Meeting of the American Society of Hematology.

last updated on Thursday, April 09, 2015